Anti-TRIM17 Polyclonal Antibody for Western Blot and ELISA - Q9Y577

Core Product Specifications and Parameters

Biological Background: TRIM17 Function and Localization

• TRIM17 (tripartite motif-containing 17), also known as RNF16, TERF, or RBCC, is a member of the TRIM/RBCC family bearing a RING finger, B-box, and coiled-coil domains.
• Acts as an E3 ubiquitin ligase that plays important roles in the regulation of neuronal apoptosis, selective autophagy, and cell proliferation. Related references: PMID:19358823 PMID:22023800 PMID:27562068
• Stimulates proteasome-dependent degradation of the kinetochore protein ZWINT, thereby negatively regulating cell proliferation.
• Inhibits autophagic degradation by assembling MCL1 into complexes with BECN1, and is required for midbody autophagy.
• Controls neuronal apoptosis through ubiquitination and degradation of MCL1.
• Localizes to the cytoplasm and lysosomes.
• Almost exclusively expressed in testis.
• The protein bears metal-binding zinc finger motifs, consistent with its transferase activity, and undergoes alternative splicing to produce multiple isoforms.

Experimental Guidance and Technical Tips

• The immunogen spans amino acids 280-477, covering the C‑terminal region including the B30.2/SPRY domain and coiled‑coil motif; consider that the antibody may detect isoforms retaining this region.
• For Western blot, the predicted molecular weight is ~54 kDa; validate with appropriate positive controls (e.g., testis lysates) and confirm specificity in your sample system.
• In ELISA applications, ensure the coating antigen matches the immunogen region for optimal detection.
• Reported cross‑reactivity with mouse and rat orthologs should be verified experimentally in each species.
• Given the testis‑specific expression, consider using testis‑derived samples for expression studies.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio offers this TRIM17 polyclonal antibody as part of a comprehensive catalog of IVD raw materials dedicated to ubiquitination, neuronal apoptosis, and autophagy research. Our portfolio includes validated antibody pairs, optimized monoclonal and polyclonal antibodies, bulk ancillary reagents, and tailored sourcing support for rare-target projects. Partner with us to accelerate your assay development from concept to clinic.